223761-22-6

Basic information

• Product Name: tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(thiazol-2-yl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate
• Synonyms: tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(thiazol-2-yl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate
• CAS NO: 223761-22-6
• Molecular Weight: 638.827
• Mol File: 223761-22-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(thiazol-2-yl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(thiazol-2-yl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate(223761-22-6)
• EPA Substance Registry System: tert-butyl (2S)-2-{2-(4-fluorophenethyl)-5-[1-(thiazol-2-yl)-2-(1-methylimidazol-5-yl)ethoxy]benzoylamino}-4-methylsulfanylbutyrate(223761-22-6)

Safety Data

• Hazardous Substances Data: 223761-22-6(Hazardous Substances Data)

Upstream product

• 223761-21-5 2-(4-fluorophenethyl)-5-[2-(1-methylimidazol-5-yl)-1-(thiazol-2-yl)ethoxy]benzoic acid 
• 91183-71-0 L-methionine-tert-butyl-ester.HCl 

Relevant articles and documents

Imidazole derivatives and their use as farnesyl protein transferase inhibitors

The present invention relates to compounds of formula (I), wherein Ar1represents (A) and (B) or (C); R12and R13are independently hydrogen or C1-4alkyl; Ar2is phenyl or heteroaryl; p is 0 or 1; Ar3is phenyl, pyridinyl, pyridazinyl, pyrimidyl or pyrazynyl, the ring being substituted on ring carbon atoms by R2and —(CH2)nR3, and wherein Ar3is attached to Ar1C(R12)R13CH(Ar2)O— by a ring carbon atom; R2is a group of formula (2), or R2represents a lactone of formula (3), the group of formula (2) or (3) havingLorDconfiguration at the chiral alpha carbon in the corresponding free amino acid; n is 0, 1 or 2; R3is phenyl or heteroaryl; and R5-R9, m and n are as defined in the specification; or a pharmaceutically acceptable salt, prodrug or solvate thereof. Processes for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them. A particular use in cancer therapy.